FireCyte Therapeutics

Executive Summary

FireCyte Therapeutics is a San Diego-based private biotechnology company founded in 2018, focused on developing targeted therapies for neurodegenerative and ophthalmic diseases by modulating microglial activation and directly protecting neurons. The company's innovative approach aims to mitigate risk by targeting well-validated pathways in neuroinflammation, with an initial emphasis on retinal diseases such as geographic atrophy and diabetic retinopathy. FireCyte's science is grounded in research on microglial biology, seeking to shift these immune cells from a pro-inflammatory to a neuroprotective state while also shielding neurons from toxic insults. This dual mechanism could offer a differentiated therapeutic strategy compared to existing anti-inflammatory approaches. The company is still in early-stage development, with no disclosed pipeline candidates or funding rounds, but its platform has potential to extend beyond ophthalmology into broader neurodegenerative conditions like Alzheimer's and multiple sclerosis, leveraging a shared microglial dysfunction component. FireCyte represents a risk-mitigated neuroscience play with a clear path to proof-of-concept in the eye given the accessibility of retinal tissue for clinical trials.

Upcoming Catalysts (preview)

• Q1 2027Lead Program IND Filing30% success
• Q2 2026Series A Financing Announcement60% success
• Q4 2026Preclinical Data Presentation at Major Conference50% success